Allergan plc

An analysis of $1B+ takeouts in 2016-24 finds biotechs opting for the billion dollar exit door in robust numbers

Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy

With $100M in series A funding, ‘2.0’ gene therapy company aims to treat retinitis pigmentosa using a channelrhodopsin variant designed for greater light sensitivity

Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues

Provided regulators clear deal, pharma sees $10B+ in added revenue from ADC company by early next decade

Plus: Full approval for Jemperli and updates from AZ, Regeneron, Prokarium and more

Plus: Flagship launches Montai and updates from Peroxitech, Tellus, Ascentage, Aeon, Genomics England, Metriopharm

With a first-in-class rich pipeline and eyes on next-gen technologies, Seagen is carving a differentiated position

Plus Baroldi, Bastings join Ionis, and updates from Exscientia, 

Japanese biotech gets improved terms with more development milestones, Japan rights for M1 program